Development of Siglec-9 Blocking Antibody to Enhance Anti-Tumor Immunity.
Development of Siglec-9 Blocking Antibody to Enhance Anti-Tumor Immunity.
复制标题
DOI:
10.3389/fonc.2021.778989
复制
发表时间:
2021
影响因子:
4.7
通讯作者:
Muthumani K
中科院分区:
文献类型:
--
作者:
Choi H;Ho M;Adeniji OS;Giron L;Bordoloi D;Kulkarni AJ;Puchalt AP;Abdel-Mohsen M;Muthumani K
Sialic acid-binding Immunoglobulin-like lectin-9 (Siglec-9) is a glyco-immune negative checkpoint expressed on several immune cells. Siglec-9 exerts its inhibitory effects by binding to sialoglycan ligands expressed on cancer cells, enabling them to evade immunosurveillance. We developed a panel of human anti-Siglec-9 hybridoma clones by immunizing mice with Siglec-9-encoding DNA and Siglec-9 protein. The lead antibodies, with high specificity and functionality against Siglec-9, were identified through screening of clones. The in vitro cytotoxicity assays showed that our lead antibody enhances anti-tumor immune activity. Further, in vivo testing utilizing ovarian cancer humanized mouse model showed a drastic reduction in tumor volume. Together, we developed novel antibodies that augment anti-tumor immunity through interference with Siglec-9-mediated immunosuppression.
登录
查看更多内容
影响因子:
6
作者:
Rosenstock P;Kaufmann T
通讯作者:
Kaufmann T
DOI:
10.1038/nrc3239
发表时间:
2012-03-22
期刊:
Nature reviews. Cancer
影响因子:
--
作者:
Pardoll DM
通讯作者:
Pardoll DM
影响因子:
29.7
作者:
Pillai S;Netravali IA;Cariappa A;Mattoo H
通讯作者:
Mattoo H
影响因子:
30.5
作者:
Beatson R;Tajadura-Ortega V;Achkova D;Picco G;Tsourouktsoglou TD;Klausing S;Hillier M;Maher J;Noll T;Crocker PR;Taylor-Papadimitriou J;Burchell JM
通讯作者:
Burchell JM
影响因子:
32.4
作者:
Patel SA;Minn AJ
通讯作者:
Minn AJ